DMAC
NASDAQ HealthcareDiaMedica Therapeutics Inc. - Common Stock
Biotechnology
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
๐ Market Data
| Price | $6.18 |
|---|---|
| Volume | 191,206 |
| Market Cap | 332.99M |
| Beta | 1.150 |
| RSI (14-Day) | 47.0 |
| 200-Day MA | $7.04 |
| 50-Day MA | $7.00 |
| 52-Week High | $10.42 |
| 52-Week Low | $3.48 |
| Forward P/E | -7.39 |
| Price / Book | 5.92 |
๐ฏ Investment Strategy Scores
DMAC scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ช Falling Knife (80/100) โ this strategy Contrarian plays (oversold + below moving average).
Lowest fit among scored strategies: ๐ Institutional Whale (7/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find DMAC in your text
Paste any article, transcript, or post โ the tool will extract DMAC and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.